InvestorsHub Logo
Followers 12
Posts 2174
Boards Moderated 0
Alias Born 03/17/2010

Re: None

Monday, 07/24/2017 12:27:55 AM

Monday, July 24, 2017 12:27:55 AM

Post# of 6305
It would have been better for us (as investors) if the last news was about two new conversions, not two old conversions continuing to improve. But that news was nonetheless encouraging (for the patients and for the long term effectiveness of the therapy) - and thus welcome.

But I would still like to see one or more patients convert before their 6 months are up - when was our last PR on a new conversion? The company was supposed to gather more recent stats for the FDA on the current SOC effectiveness. If recent SOC stats indicate more success than in the past, it would be advantageous if the scaffold stats were even more dramatic.

I added a few shares last week lowering my cost basis to 4.69. While I was glad to add at a great price, I'm still under water. But I'm staying long, waiting for the next positive PR.

There are a number of conditions that have no effective treatment - ALS and Alzheimer's come to mind. SPI is another. If we can get this trial successfully concluded (I think we will), then imo 2.20 will be a gift. On the other hand, if the trial fails, then 2.20 is no gift!